CTRI/2022/10/046782
Not yet recruiting
未知
Impact of Injectable contraceptive-DepotMedroxyprogesterone Acetate (DMPA) Administration on selected outcome measures.
Rajalakshmi R0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Rajalakshmi R
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female taking Injectable Contraceptive\-DMPA
Exclusion Criteria
- •Undiagnosed Vaginal Or Urinary Tract Bleeding
- •Breast Cancer
- •Poorly Controlled Hypertension
- •Multiple Cardiovascular Risk Factors
- •Sever Hepatic Dysfunction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell DiseaseSickle Cell Disease (SCD)Vaso-Occlusive Pain Episode in Sickle Cell DiseaseNCT06665997University of Pennsylvania65
Recruiting
Not Applicable
The WHICH injection study (Part 1)Mental and Behavioural DisordersPACTR202009758229976niversity of Fort Hare520
Not yet recruiting
Phase 3
Comparing two drugs for a treatmentCTRI/2024/03/064357SRM college of pharamacy
Completed
Not Applicable
Depot-medroxy Progesterone Acetate Injectable Contraceptives in Lactating Women 1st Week Versus 6 Week Postpartum InitiationComplications of DMPA Injectable ContraceptivesNCT06100783Assiut University120
Recruiting
Phase 3
Effect of Medroxy progesteron in Chronic Obstructive Pulmonary Disease (COPD) exacerbatioChronic Obstructive Pulmonary Disease(COPD) Exacerbation.Chronic obstructive pulmonary disease with acute exacerbation, unspecifiedJ44.1IRCT20211031052922N1Esfahan University of Medical Sciences70